Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지
DOI QR코드

DOI QR Code

Stereotactic Body Radiation Therapy in Canine Nasal Transitional Cell Carcinoma

  • Received : 2017.01.13
  • Accepted : 2017.08.11
  • Published : 2017.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

An 11-year-old neutered male Maltese presented for radiation therapy for nasal transitional cell carcinoma. Stereotactic body radiation therapy (SBRT) was provided for the owner's request. Clinical signs improved 6 days after radiation therapy. Adverse effects including alopecia and pigmentation on the facial region were observed at 21 days after radiation therapy. The first follow-up computed tomography (CT) 96 days after SBRT revealed that the nasal tumor had decreased by 60.63% compared with the pre-treatment volume. Clinical signs related with the tumor reassigned 151 days after SBRT, and the second follow-up CT revealed tumor relapse. The patient was died 238 days after SBRT due to tumor relapse. SBRT showed a good tumor control effect with relatively mild radiation toxicity relative to other radiation therapy modalities, in accordance with a previous study. Further studies are needed to establish an effective treatment protocol, such as total dose, fractional dose, and inter-fractional period, in canine malignant nasal tumors.

Keywords

References

  1. Adams WM, Kleiter MM., Thrall DE, Klauer JM, Forrest LJ, La Due TA, Havinghurst TC. Prognostic significance of tumor histology and computed tomographic staging for radiation treatment response of canine nasal tumors. Vet Radiol Ultrasound 2009; 50: 330-335. https://doi.org/10.1111/j.1740-8261.2009.01545.x
  2. Astrahan M. Some implications of linear-quadratic-linear radiation dose-response with regard to hypofraction. Med Phys 2008; 35: 4161-4172. https://doi.org/10.1118/1.2969065
  3. Bonkobara M. Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Vet J 2015; 205: 180-188. https://doi.org/10.1016/j.tvjl.2014.12.015
  4. Cancedda S, Sabattini S, Bettini G, Leone VF, Laganga P, Rossi F, Terragni R, Gnudi G, Vignoli M. Combination of radiation therapy and firocoxib for the treatment of canine nasal carcinoma. Vet Radiol Ultrasound 2015; 56: 335-343. https://doi.org/10.1111/vru.12246
  5. Coste-Maniere E, Olender D, Kilby W, Schulz RA. Robotic whole body stereotactic radiosurgery: Clinical advantages of the CyberKnife(R) integrated system. Int J Med Robot Comp 2005; 1: 28-39. https://doi.org/10.1002/rcs.39
  6. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653. https://doi.org/10.1182/blood-2004-08-3097
  7. Fowler JF. 21 years of biologically effective dose. Br J Radiol 2010; 83: 554-568. https://doi.org/10.1259/bjr/31372149
  8. Glasser SA, Charmey S, Dervisis NG, Witten MR, Ettinger S, Berg J, Joseph R. Use of an image-guided robotic radiosurgery system for the treatment of canine nonlymphomatous nasal tumors. J Am Anim Hosp Assoc 2014; 50: 96-104. https://doi.org/10.5326/JAAHA-MS-6024
  9. Guerrero M, Li XA. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 2004; 49: 4825-4835. https://doi.org/10.1088/0031-9155/49/20/012
  10. Hall EJ, Giaccia AJ. Time, Dose, and Fractionation in Radiotherapy. In: Radiobiology for the radiologist, 7th ed. Philadelphia: Lippincott Williams & Wilkins. 2012: 391-411.
  11. Hunley DW, Mauldin GN, Shiomitsu K Mauldin GE. Clinical outcome in dogs with nasal tumors treated with intensity-modulated radiation therapy. Can Vet J 2010; 51: 293-300.
  12. LaDue T, Klein MK. Toxicity criteria of the veterinary radiation therapy oncology group. Vet Radiol Ultrasound 2001; 5: 475-476.
  13. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009; 24: 106-112. https://doi.org/10.1053/j.tcam.2009.02.002
  14. London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, Ettinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, Ladue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, Henry C, Gillings S. Preliminary evidence for biologic activity of toceranib phosphate ($Palladia^{(R)}$) in solid tumours. Vet Comp Oncol 2011; 10: 194-205.
  15. Ozyugut G, Cengiz M, Hurmuz P, Gultekin M, Akyol F, Yildiz F, Gurkaynak M, Zorlu F. Robotic stereotactic radiosurgery in patients with nasal cavity and paranasal sinus tumors. Technol Cancer Res Treat 2014; 13: 409-413.
  16. Pandey R, Gurumurthy, Haddad A, Dhaduk P. Stereotactic body radiation therapy: A review of applications and outcomes. J Nuci Med Radiat Ther 2015; 6: 229.
  17. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 847-852. https://doi.org/10.1016/j.ijrobp.2007.10.059
  18. Rassnick KM, Goldkamp CE, Erb HN, Scrivani PV, Njaa BL, Gieger TL, Turek MM, McNiel EA, Proulx DR, Chun R, Mauldin GE, Phillips BS, Kristal O. Evaluation of factors associated with survival in dogs with untreated nasal carcinoma. J Am Vet Med Assoc 2006; 229: 401-406. https://doi.org/10.2460/javma.229.3.401
  19. Shibamoto Y, Otsuka S, Iwata H, Sugie C, Ogino H, Tomita N. Radiobiological evaluation of the radiation dose as used in high-precision radiotherapy: Effect of prolonged delivery time and applicability of the linear-quadratic model. J Radiat Res 2012; 53: 1-9. https://doi.org/10.1269/jrr.11095
  20. Shiomitsu K, Johnson CL, Malarkey DE, Pruitt AF, Thrall DE. Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. Vet Comp Oncol 2009; 7: 106-114. https://doi.org/10.1111/j.1476-5829.2008.00178.x
  21. Turek MM. Canine nasosinal tumors. In: Withrow & Mac- Ewen's Small Animal Clinical Oncology, 5th ed. St. Louis: Saunders Elsevier. 2013: 435-446.
  22. Zhang H, Das I, Wilson J, Uzan J, Lasley F, Cardenes H. Evaluation of tumor control probability of stereotactic body radiation therapy (SBRT) for primary liver cancers. Int J Radiat Oncol 2013; 87: S691-S692.